Aptamers - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Aptamers Market Summary
Overview
Aptamers Market Key Growth Drivers
The leading participants in the aptamers market include the following:
Market Drivers
Regulatory Validation of Aptamer-Based Therapeutics
The foundational driver reshaping the aptamers market is the regulatory validation of aptamer-based therapeutics following the FDA's August 2023 approval of avacincaptad pegol, marketed as Izervay, for geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol, an RNA aptamer covalently linked to branched polyethylene glycol molecules that binds complement protein C5 and inhibits its cleavage into C5a and C5b, was approved based on positive results from the Phase 3 GATHER1 and GATHER2 clinical trials demonstrating a statistically significant reduction in the growth rate of geographic atrophy. This approval, only the second for an aptamer drug following pegaptanib's 2004 approval for neovascular age-related macular degeneration, renewed pharmaceutical industry interest in aptamer-based drug development and provided a template confirming that nucleic acid aptamers can meet clinical, manufacturing, and regulatory standards when target biology, chemical modification, and delivery are well matched. As additional aptamer therapeutic candidates advance through clinical development following this regulatory precedent, demand for aptamer discovery, synthesis, and manufacturing capability grows across the forecast period.
Sustained Growth in Aptamer-Based Proteomics and Diagnostics
Sustained growth in aptamer-based proteomics and diagnostics platforms reflects the expanding role of SOMAmer reagent technology in large-scale biomarker discovery and personalized medicine research. In April 2025, SomaLogic announced the launch of a novel aptamer-based proteomics platform designed to enhance biomarker discovery and accelerate personalized medicine applications, improving sensitivity and specificity in diagnostic assays for early disease detection and monitoring. As pharmaceutical and academic researchers continue to rely on high-throughput, aptamer-based proteomics platforms for biomarker discovery across oncology, cardiovascular disease, and other therapeutic areas, demand for these platforms and their associated reagents grows across the forecast period.
Market Restraints
The aptamers market faces several interrelated restraints that temper its growth. The labor-intensive and time-consuming nature of conventional SELEX-based aptamer discovery, even as AI-assisted approaches begin to address this limitation, continues to constrain the pace at which new aptamer candidates can be identified and validated relative to some competing binding reagent technologies. Nuclease degradation and rapid renal clearance remain persistent challenges for unmodified aptamer therapeutics, requiring chemical modification strategies such as PEGylation or mirror-image Spiegelmer chemistry that add cost and development complexity. The limited number of FDA-approved aptamer therapeutics to date, with only two approvals across more than two decades since pegaptanib's 2004 approval, means the clinical and commercial validation of aptamer-based drug development remains earlier-stage relative to more established therapeutic modalities such as monoclonal antibodies. Competition from alternative affinity reagent technologies, including monoclonal and single-domain antibodies and increasingly sophisticated antibody engineering platforms, provides an alternative path for many diagnostic and therapeutic applications that does not require aptamer-specific development expertise. Manufacturing scale-up and chemistry, manufacturing, and controls documentation for oligonucleotide impurities, while clarified by FDA guidance following Izervay's approval, remain a specialized regulatory and technical area that can complicate aptamer therapeutic development relative to small-molecule or antibody drug programs. Together, these factors moderate the pace of adoption and require aptamer developers to demonstrate discovery speed, chemical stability, and regulatory precedent to sustain growth.
Aptamers Market Segment Analysis
The global aptamers market is segmented by type (DNA aptamers, RNA aptamers, and peptide aptamers), by application (diagnostics, therapeutics, drug discovery and target validation, and biosensors and research reagents), by technology (conventional SELEX and AI-assisted/computational aptamer discovery), by end-user (pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and contract research organizations), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Application
Dominant Subsegment: Diagnostics.
The diagnostics category is expected to dominate the market. Diagnostics, led by SOMAmer reagent-based proteomics platforms now under Illumina following its 2026 acquisition of SomaLogic, is the leading application because aptamer-based proteomics technology has achieved broad adoption for high-throughput biomarker discovery across academic and pharmaceutical research, representing the most commercially mature and widely deployed aptamer application to date. The dominance of the segment reflects the scale of the installed base of aptamer-based proteomics platforms and the depth of biomarker discovery research built around this technology. Therapeutics represented the fastest-growing application in 2025, driven by the regulatory momentum following avacincaptad pegol's FDA approval and Japanese regulatory filing, and by continued clinical development of pipeline candidates including TME Pharma's NOX-A12 and other Spiegelmer therapeutics, while drug discovery and target validation and biosensor and research reagent applications remain substantial and growing categories.
By Type
Dominant Subsegment: RNA Aptamers.
The RNA aptamers category is expected to dominate the market. RNA aptamers, including both conventional RNA aptamers and chemically modified variants such as TME Pharma's mirror-image L-RNA Spiegelmer platform and Astellas's PEGylated RNA aptamer avacincaptad pegol, are the leading type because RNA aptamers underlie both of the two FDA-approved aptamer drugs to date and because RNA-based chemistry has demonstrated the strongest clinical validation and commercial track record within the aptamer field. The dominance of the segment reflects the depth of clinical and regulatory precedent established by pegaptanib and avacincaptad pegol. DNA aptamers remain a substantial category, particularly for diagnostic and research reagent applications where their greater chemical stability and lower synthesis cost are advantageous, while peptide aptamers represent a smaller, more specialized category.
Aptamers Market Region Analysis
Dominant Region: North America
North America accounted for a 44% share of the global aptamers market in 2025, representing the highest regional market share globally. The leadership of the region reflects an established biotechnology ecosystem, a supportive regulatory framework demonstrated by FDA approval of both aptamer drugs to date, and the concentration of leading organizations including Illumina, Base Pair Biotechnologies, and NeoVentures Biotechnology. The United States is the largest national market, supported by substantial biopharmaceutical research and development investment, robust public health emergency preparedness funding, and the concentration of aptamer proteomics and therapeutic development activity. The concentration of vendors, regulatory precedent, and research investment reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding biopharmaceutical research infrastructure and pursuing regulatory approval for aptamer therapeutics, exemplified by Astellas Pharma's February 2025 New Drug Application submission in Japan for avacincaptad pegol, which would become Japan's first available therapy for geographic atrophy if approved. China, Japan, and India are the principal national markets, supported by expanding academic and biotechnology research capacity and growing regional regulatory engagement with novel aptamer-based therapeutics and diagnostics. As regional regulatory approval activity continues and as biomedical research infrastructure expands, Asia-Pacific is positioned as the fastest-growing regional market across the forecast period.
Regional Commentary
North America
North America leads the market, supported by an established biotechnology ecosystem, supportive regulatory precedent, and the concentration of leading organizations. The United States dominates the region through its concentration of companies and aptamer therapeutic and diagnostic development activity.
Europe
Europe is a substantial market shaped by strong academic research infrastructure and the presence of leading organizations including Aptamer Group and TME Pharma. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the United Kingdom in particular anchors the region's aptamer diagnostics research base through Aptamer Group.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by expanding biopharmaceutical research infrastructure and growing regulatory engagement with aptamer therapeutics, exemplified by Japan's pending review of avacincaptad pegol.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as biomedical research infrastructure expands, though adoption of advanced aptamer technology remains concentrated in leading academic and private research centers.
Aptamers Market Competitive Landscape
The global aptamers market is classified as Moderately Consolidated. Illumina, following its 2026 acquisition of SomaLogic, holds a substantial share of the market through its aptamer-based proteomics platform, while a broader group of specialist aptamer discovery and development companies, including Aptamer Group, Base Pair Biotechnologies, NeoVentures Biotechnology, and TriLink BioTechnologies, compete on custom aptamer discovery services, and pharmaceutical companies including Astellas Pharma and TME Pharma advance aptamer-based therapeutic candidates. Competition centers on breadth of aptamer discovery and chemical modification capability, depth of proteomics platform integration, clinical and regulatory precedent for therapeutic candidates, and the pace of AI-assisted discovery adoption. The competitive landscape is evaluated across the following dimensions:
Aptamers Market Assessment by Type
â—¦ Mirror-Image L-RNA Spiegelmer Aptamers
Canada Aptamers Market Size in USD million (2023-2034)
Mexico Aptamers Market Size in USD million (2023-2034)
United Kingdom Aptamers Market Size in USD million (2023-2034)
France Aptamers Market Size in USD million (2023-2034)
Italy Aptamers Market Size in USD million (2023-2034)
Spain Aptamers Market Size in USD million (2023-2034)
Rest of Europe Aptamers Market Size in USD million (2023-2034)
Japan Aptamers Market Size in USD million (2023-2034)
India Aptamers Market Size in USD million (2023-2034)
Australia Aptamers Market Size in USD million (2023-2034)
South Korea Aptamers Market Size in USD million (2023-2034)
Rest of Asia-Pacific Aptamers Market Size in USD million (2023-2034)
Africa Aptamers Market Size in USD million (2023-2034)
South America Aptamers Market Size in USD million (2023-2034)
Key Takeaways from the Aptamers Market Report Study
Q1. At what rate is the aptamers market expected to grow?
The global aptamers market is projected to grow at a compound annual growth rate of 14.5% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the aptamers market?
The global aptamers market was valued at USD 1.6 billion in 2025 and is projected to reach USD 5.5 billion by 2034.
Q3. Which region dominates the aptamers market?
North America dominated the aptamers market with a 44% share in 2025, driven by an established biotechnology ecosystem and supportive regulatory precedent. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by expanding regulatory engagement with aptamer therapeutics, including Japan's pending review of avacincaptad pegol.
Q4. What are the key factors driving growth in the aptamers market?
The principal drivers are the regulatory validation of aptamer-based therapeutics following the FDA's 2023 approval of avacincaptad pegol; sustained growth in aptamer-based proteomics and diagnostics; consolidation of proteomics assets under major genomics companies; emerging AI-assisted aptamer discovery technology; and growing international regulatory activity for aptamer therapeutics.
Q5. Who are the major players in the aptamers market?
The market is moderately consolidated and led by Illumina, Inc. through its SomaLogic business and Astellas Pharma Inc. through its Izervay franchise, alongside Aptamer Group plc, Base Pair Biotechnologies, Inc., NeoVentures Biotechnology Inc., TriLink BioTechnologies, LLC, TME Pharma AG, Aptagen LLC, Vivonics Inc., and NEC Corporation.
Overview
- The global aptamers market was valued at USD 1.6 billion in 2025 and is projected to reach USD 5.5 billion by 2034.
- The market is expected to expand at a CAGR of 14.5% during the forecast period 2026-2034, supported by the regulatory validation of aptamer-based therapeutics following the FDA's 2023 approval of avacincaptad pegol, sustained growth in aptamer-based proteomics and diagnostics platforms, consolidation of leading aptamer proteomics assets under major genomics companies, and emerging application of artificial intelligence to accelerate SELEX-based aptamer discovery.
- By application, diagnostics dominated the aptamers market in 2025, while therapeutics represented the fastest-growing application.
- By type, RNA aptamers dominated the aptamers market in 2025.
- By technology, conventional SELEX (Systematic Evolution of Ligands by Exponential Enrichment) dominated the aptamers market in 2025, while AI-assisted and computational aptamer discovery represented the fastest-growing technology.
- North America accounted for the largest share of the aptamers market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.
Aptamers Market Key Growth Drivers
- Regulatory validation of aptamer-based therapeutics following the FDA's August 2023 approval of avacincaptad pegol (Izervay) for geographic atrophy secondary to age-related macular degeneration, only the second FDA-approved aptamer drug after pegaptanib in 2004.
- Sustained growth in aptamer-based proteomics and diagnostics platforms, exemplified by the SOMAscan platform's continued expansion of biomarker discovery and personalized medicine applications.
- Consolidation of leading aptamer proteomics assets under major genomics companies, exemplified by Illumina's January 2026 acquisition of SomaLogic and related assets from Standard BioTools for USD 350 million upfront plus up to USD 75 million in milestone payments.
- Emerging application of artificial intelligence to accelerate SELEX-based aptamer discovery, exemplified by TME Pharma's January 2025 collaboration with Aimed Analytics to integrate deep learning with oligonucleotide drug development.
- Growing international regulatory activity for aptamer therapeutics, exemplified by Astellas Pharma's February 2025 New Drug Application submission in Japan for avacincaptad pegol, which would become Japan's first available therapy for geographic atrophy if approved.
- Continued advancement of chemically modified aptamer platforms, including PEGylation and mirror-image L-RNA Spiegelmer chemistry, that improve pharmacokinetic half-life and reduce nuclease degradation relative to earlier-generation aptamer constructs.
- Expanding use of aptamers as antibody alternatives in diagnostics and biosensor applications, favored for their chemical stability, low immunogenicity, and lower-cost, animal-free synthetic production relative to antibody manufacturing.
The leading participants in the aptamers market include the following:
- Illumina, Inc. (SomaLogic)
- Aptamer Group plc
- Base Pair Biotechnologies, Inc.
- NeoVentures Biotechnology Inc.
- TriLink BioTechnologies, LLC (Maravai LifeSciences)
- TME Pharma AG
- Astellas Pharma Inc.
- Aptagen LLC
- Vivonics Inc.
- NEC Corporation
Market Drivers
Regulatory Validation of Aptamer-Based Therapeutics
The foundational driver reshaping the aptamers market is the regulatory validation of aptamer-based therapeutics following the FDA's August 2023 approval of avacincaptad pegol, marketed as Izervay, for geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol, an RNA aptamer covalently linked to branched polyethylene glycol molecules that binds complement protein C5 and inhibits its cleavage into C5a and C5b, was approved based on positive results from the Phase 3 GATHER1 and GATHER2 clinical trials demonstrating a statistically significant reduction in the growth rate of geographic atrophy. This approval, only the second for an aptamer drug following pegaptanib's 2004 approval for neovascular age-related macular degeneration, renewed pharmaceutical industry interest in aptamer-based drug development and provided a template confirming that nucleic acid aptamers can meet clinical, manufacturing, and regulatory standards when target biology, chemical modification, and delivery are well matched. As additional aptamer therapeutic candidates advance through clinical development following this regulatory precedent, demand for aptamer discovery, synthesis, and manufacturing capability grows across the forecast period.
Sustained Growth in Aptamer-Based Proteomics and Diagnostics
Sustained growth in aptamer-based proteomics and diagnostics platforms reflects the expanding role of SOMAmer reagent technology in large-scale biomarker discovery and personalized medicine research. In April 2025, SomaLogic announced the launch of a novel aptamer-based proteomics platform designed to enhance biomarker discovery and accelerate personalized medicine applications, improving sensitivity and specificity in diagnostic assays for early disease detection and monitoring. As pharmaceutical and academic researchers continue to rely on high-throughput, aptamer-based proteomics platforms for biomarker discovery across oncology, cardiovascular disease, and other therapeutic areas, demand for these platforms and their associated reagents grows across the forecast period.
Market Restraints
The aptamers market faces several interrelated restraints that temper its growth. The labor-intensive and time-consuming nature of conventional SELEX-based aptamer discovery, even as AI-assisted approaches begin to address this limitation, continues to constrain the pace at which new aptamer candidates can be identified and validated relative to some competing binding reagent technologies. Nuclease degradation and rapid renal clearance remain persistent challenges for unmodified aptamer therapeutics, requiring chemical modification strategies such as PEGylation or mirror-image Spiegelmer chemistry that add cost and development complexity. The limited number of FDA-approved aptamer therapeutics to date, with only two approvals across more than two decades since pegaptanib's 2004 approval, means the clinical and commercial validation of aptamer-based drug development remains earlier-stage relative to more established therapeutic modalities such as monoclonal antibodies. Competition from alternative affinity reagent technologies, including monoclonal and single-domain antibodies and increasingly sophisticated antibody engineering platforms, provides an alternative path for many diagnostic and therapeutic applications that does not require aptamer-specific development expertise. Manufacturing scale-up and chemistry, manufacturing, and controls documentation for oligonucleotide impurities, while clarified by FDA guidance following Izervay's approval, remain a specialized regulatory and technical area that can complicate aptamer therapeutic development relative to small-molecule or antibody drug programs. Together, these factors moderate the pace of adoption and require aptamer developers to demonstrate discovery speed, chemical stability, and regulatory precedent to sustain growth.
Aptamers Market Segment Analysis
The global aptamers market is segmented by type (DNA aptamers, RNA aptamers, and peptide aptamers), by application (diagnostics, therapeutics, drug discovery and target validation, and biosensors and research reagents), by technology (conventional SELEX and AI-assisted/computational aptamer discovery), by end-user (pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and contract research organizations), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Application
Dominant Subsegment: Diagnostics.
The diagnostics category is expected to dominate the market. Diagnostics, led by SOMAmer reagent-based proteomics platforms now under Illumina following its 2026 acquisition of SomaLogic, is the leading application because aptamer-based proteomics technology has achieved broad adoption for high-throughput biomarker discovery across academic and pharmaceutical research, representing the most commercially mature and widely deployed aptamer application to date. The dominance of the segment reflects the scale of the installed base of aptamer-based proteomics platforms and the depth of biomarker discovery research built around this technology. Therapeutics represented the fastest-growing application in 2025, driven by the regulatory momentum following avacincaptad pegol's FDA approval and Japanese regulatory filing, and by continued clinical development of pipeline candidates including TME Pharma's NOX-A12 and other Spiegelmer therapeutics, while drug discovery and target validation and biosensor and research reagent applications remain substantial and growing categories.
By Type
Dominant Subsegment: RNA Aptamers.
The RNA aptamers category is expected to dominate the market. RNA aptamers, including both conventional RNA aptamers and chemically modified variants such as TME Pharma's mirror-image L-RNA Spiegelmer platform and Astellas's PEGylated RNA aptamer avacincaptad pegol, are the leading type because RNA aptamers underlie both of the two FDA-approved aptamer drugs to date and because RNA-based chemistry has demonstrated the strongest clinical validation and commercial track record within the aptamer field. The dominance of the segment reflects the depth of clinical and regulatory precedent established by pegaptanib and avacincaptad pegol. DNA aptamers remain a substantial category, particularly for diagnostic and research reagent applications where their greater chemical stability and lower synthesis cost are advantageous, while peptide aptamers represent a smaller, more specialized category.
Aptamers Market Region Analysis
Dominant Region: North America
North America accounted for a 44% share of the global aptamers market in 2025, representing the highest regional market share globally. The leadership of the region reflects an established biotechnology ecosystem, a supportive regulatory framework demonstrated by FDA approval of both aptamer drugs to date, and the concentration of leading organizations including Illumina, Base Pair Biotechnologies, and NeoVentures Biotechnology. The United States is the largest national market, supported by substantial biopharmaceutical research and development investment, robust public health emergency preparedness funding, and the concentration of aptamer proteomics and therapeutic development activity. The concentration of vendors, regulatory precedent, and research investment reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding biopharmaceutical research infrastructure and pursuing regulatory approval for aptamer therapeutics, exemplified by Astellas Pharma's February 2025 New Drug Application submission in Japan for avacincaptad pegol, which would become Japan's first available therapy for geographic atrophy if approved. China, Japan, and India are the principal national markets, supported by expanding academic and biotechnology research capacity and growing regional regulatory engagement with novel aptamer-based therapeutics and diagnostics. As regional regulatory approval activity continues and as biomedical research infrastructure expands, Asia-Pacific is positioned as the fastest-growing regional market across the forecast period.
Regional Commentary
North America
North America leads the market, supported by an established biotechnology ecosystem, supportive regulatory precedent, and the concentration of leading organizations. The United States dominates the region through its concentration of companies and aptamer therapeutic and diagnostic development activity.
Europe
Europe is a substantial market shaped by strong academic research infrastructure and the presence of leading organizations including Aptamer Group and TME Pharma. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the United Kingdom in particular anchors the region's aptamer diagnostics research base through Aptamer Group.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by expanding biopharmaceutical research infrastructure and growing regulatory engagement with aptamer therapeutics, exemplified by Japan's pending review of avacincaptad pegol.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as biomedical research infrastructure expands, though adoption of advanced aptamer technology remains concentrated in leading academic and private research centers.
Aptamers Market Competitive Landscape
The global aptamers market is classified as Moderately Consolidated. Illumina, following its 2026 acquisition of SomaLogic, holds a substantial share of the market through its aptamer-based proteomics platform, while a broader group of specialist aptamer discovery and development companies, including Aptamer Group, Base Pair Biotechnologies, NeoVentures Biotechnology, and TriLink BioTechnologies, compete on custom aptamer discovery services, and pharmaceutical companies including Astellas Pharma and TME Pharma advance aptamer-based therapeutic candidates. Competition centers on breadth of aptamer discovery and chemical modification capability, depth of proteomics platform integration, clinical and regulatory precedent for therapeutic candidates, and the pace of AI-assisted discovery adoption. The competitive landscape is evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with Illumina/SomaLogic holding a substantial share of the proteomics platform segment, alongside Aptamer Group, Base Pair Biotechnologies, NeoVentures Biotechnology, TriLink BioTechnologies, TME Pharma, Astellas Pharma, Aptagen, Vivonics, and NEC Corporation.
- Leading players: Illumina leads in aptamer-based proteomics through the SOMAscan platform following its 2026 SomaLogic acquisition; Astellas Pharma leads in aptamer therapeutics through its Izervay franchise, acquired via its 2023 acquisition of Iveric Bio; and Aptamer Group leads in custom aptamer discovery services through its Optimer platform.
- Geographic reach: Illumina and Astellas Pharma operate global commercial and regulatory organizations, while specialist vendors including Aptamer Group, Base Pair Biotechnologies, and NeoVentures Biotechnology maintain more concentrated footprints centered on North America and Europe.
- Product portfolio strength: Competitive advantage rests on the breadth across aptamer types and chemical modification strategies, and on the integration of aptamer discovery platforms with proteomics, diagnostics, or therapeutic development infrastructure.
- Pipeline strength: Development is concentrated in AI-assisted SELEX optimization, chemically modified aptamer platforms with extended pharmacokinetic half-life, and expanded therapeutic indications beyond ophthalmology, including autoimmune and metabolic disease.
- Strategic partnerships: Collaboration spans AI discovery partnerships, exemplified by TME Pharma's collaboration with Aimed Analytics, and manufacturing partnerships, exemplified by Aptahem's April 2025 collaboration with Hongene Biotech to lower manufacturing costs for its Apta-1 candidate.
- M&A activity: Consolidation has shaped the field, exemplified by Illumina's January 2026 acquisition of SomaLogic and related assets from Standard BioTools for USD 350 million upfront plus up to USD 75 million in milestones, following Standard BioTools' own 2024 merger with SomaLogic, and Astellas Pharma's earlier acquisition of Iveric Bio, developer of avacincaptad pegol.
- Innovation focus: Innovation is concentrated in AI-assisted and computational aptamer discovery, chemically modified and extended-half-life aptamer chemistry, and expanded diagnostic applications leveraging aptamers as antibody alternatives.
- Regulatory standing: FDA approval precedent established by pegaptanib and avacincaptad pegol, along with FDA guidance clarifying chemistry, manufacturing, and controls expectations for oligonucleotide impurities following Izervay's approval, are decisive competitive credentials shaping the aptamer therapeutics regulatory pathway.
- In January 2026, Illumina completed the acquisition of SomaLogic and related assets from Standard BioTools for USD 350 million upfront, plus up to USD 75 million in milestone payments. Strategic significance: the acquisition consolidated leading aptamer-based proteomics technology under a major genomics company, reflecting continued industry consolidation around integrated multi-omics platforms.
- In February 2025, Astellas Pharma submitted a New Drug Application in Japan for conditional approval of avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration. Strategic significance: approval would establish Japan's first available therapy for geographic atrophy and extend avacincaptad pegol's commercial reach beyond the United States.
Aptamers Market Assessment by Type
- DNA Aptamers
- RNA Aptamers
â—¦ Mirror-Image L-RNA Spiegelmer Aptamers
- Peptide Aptamers
- Diagnostics
- Therapeutics
- Drug Discovery and Target Validation
- Biosensors and Research Reagents
- Conventional SELEX
- AI-Assisted/Computational Aptamer Discovery
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Diagnostic Laboratories
- Contract Research Organizations
- North America
Canada Aptamers Market Size in USD million (2023-2034)
Mexico Aptamers Market Size in USD million (2023-2034)
- Europe
United Kingdom Aptamers Market Size in USD million (2023-2034)
France Aptamers Market Size in USD million (2023-2034)
Italy Aptamers Market Size in USD million (2023-2034)
Spain Aptamers Market Size in USD million (2023-2034)
Rest of Europe Aptamers Market Size in USD million (2023-2034)
- Asia-Pacific
Japan Aptamers Market Size in USD million (2023-2034)
India Aptamers Market Size in USD million (2023-2034)
Australia Aptamers Market Size in USD million (2023-2034)
South Korea Aptamers Market Size in USD million (2023-2034)
Rest of Asia-Pacific Aptamers Market Size in USD million (2023-2034)
- Rest of the World
Africa Aptamers Market Size in USD million (2023-2034)
South America Aptamers Market Size in USD million (2023-2034)
Key Takeaways from the Aptamers Market Report Study
- Market size analysis for the current aptamers market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product, technology, and regulatory developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global aptamers market.
- Various opportunities available for competitors in the aptamers market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current aptamers market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for aptamers market growth in the future?
- Aptamer discovery, diagnostics, and therapeutics providers
- Research organizations and consulting companies
- Genomics, proteomics, and ophthalmology-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and partners dealing in aptamer-based products and services
- Various end-users who want to know more about the aptamers market and the latest technological developments in the aptamers market.
Q1. At what rate is the aptamers market expected to grow?
The global aptamers market is projected to grow at a compound annual growth rate of 14.5% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the aptamers market?
The global aptamers market was valued at USD 1.6 billion in 2025 and is projected to reach USD 5.5 billion by 2034.
Q3. Which region dominates the aptamers market?
North America dominated the aptamers market with a 44% share in 2025, driven by an established biotechnology ecosystem and supportive regulatory precedent. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by expanding regulatory engagement with aptamer therapeutics, including Japan's pending review of avacincaptad pegol.
Q4. What are the key factors driving growth in the aptamers market?
The principal drivers are the regulatory validation of aptamer-based therapeutics following the FDA's 2023 approval of avacincaptad pegol; sustained growth in aptamer-based proteomics and diagnostics; consolidation of proteomics assets under major genomics companies; emerging AI-assisted aptamer discovery technology; and growing international regulatory activity for aptamer therapeutics.
Q5. Who are the major players in the aptamers market?
The market is moderately consolidated and led by Illumina, Inc. through its SomaLogic business and Astellas Pharma Inc. through its Izervay franchise, alongside Aptamer Group plc, Base Pair Biotechnologies, Inc., NeoVentures Biotechnology Inc., TriLink BioTechnologies, LLC, TME Pharma AG, Aptagen LLC, Vivonics Inc., and NEC Corporation.
Table of Contents
150 Pages
- 1. Aptamers Market Introduction
- 1.1. Scope of the Report
- 1.2. Market Segmentation
- 1.3. Market Overview at a Glance
- 2. Aptamers Market Executive Summary
- 2.1. Key Highlights and Market Snapshot
- 3. Aptamers Market Key Factors Analysis
- 3.1. Market Drivers
- 3.1.1. Regulatory Validation of Aptamer-Based Therapeutics
- 3.1.2. Sustained Growth in Aptamer-Based Proteomics and Diagnostics
- 3.1.3. Consolidation of Aptamer Proteomics Assets Under Major Genomics Companies
- 3.1.4. Emerging Application of AI to Accelerate SELEX-Based Discovery
- 3.2. Market Restraints
- 3.2.1. Labor-Intensive Nature of Conventional SELEX Discovery
- 3.2.2. Nuclease Degradation and Rapid Renal Clearance
- 3.2.3. Limited Number of Approved Aptamer Therapeutics
- 3.3. Market Opportunities
- 3.3.1. AI-Assisted and Computational Aptamer Discovery
- 3.3.2. International Regulatory Expansion for Approved Aptamer Drugs
- 4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
- 5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
- 6. Aptamers Market Porter's Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
- 7. Aptamers Market Assessment
- 7.1. By Type
- 7.1.1. DNA Aptamers
- 7.1.2. RNA Aptamers
- 7.1.2.1. Conventional RNA Aptamers
- 7.1.2.2. Mirror-Image L-RNA Spiegelmer Aptamers
- 7.1.3. Peptide Aptamers
- 7.2. By Application
- 7.2.1. Diagnostics
- 7.2.2. Therapeutics
- 7.2.3. Drug Discovery and Target Validation
- 7.2.4. Biosensors and Research Reagents
- 7.3. By Technology
- 7.3.1. Conventional SELEX
- 7.3.2. AI-Assisted/Computational Aptamer Discovery
- 7.4. By End-User
- 7.4.1. Pharmaceutical and Biotechnology Companies
- 7.4.2. Academic and Research Institutes
- 7.4.3. Diagnostic Laboratories
- 7.4.4. Contract Research Organizations
- 7.5. By Geography
- 7.5.1. North America
- 7.5.1.1. United States Aptamers Market Size in USD million (2023-2034)
- 7.5.1.2. Canada Aptamers Market Size in USD million (2023-2034)
- 7.5.1.3. Mexico Aptamers Market Size in USD million (2023-2034)
- 7.5.2. Europe
- 7.5.2.1. Germany Aptamers Market Size in USD million (2023-2034)
- 7.5.2.2. United Kingdom Aptamers Market Size in USD million (2023-2034)
- 7.5.2.3. France Aptamers Market Size in USD million (2023-2034)
- 7.5.2.4. Italy Aptamers Market Size in USD million (2023-2034)
- 7.5.2.5. Spain Aptamers Market Size in USD million (2023-2034)
- 7.5.2.6. Rest of Europe Aptamers Market Size in USD million (2023-2034)
- 7.5.3. Asia-Pacific
- 7.5.3.1. China Aptamers Market Size in USD million (2023-2034)
- 7.5.3.2. Japan Aptamers Market Size in USD million (2023-2034)
- 7.5.3.3. India Aptamers Market Size in USD million (2023-2034)
- 7.5.3.4. Australia Aptamers Market Size in USD million (2023-2034)
- 7.5.3.5. South Korea Aptamers Market Size in USD million (2023-2034)
- 7.5.3.6. Rest of Asia-Pacific Aptamers Market Size in USD million (2023-2034)
- 7.5.4. Rest of the World
- 7.5.4.1. Middle East Aptamers Market Size in USD million (2023-2034)
- 7.5.4.2. Africa Aptamers Market Size in USD million (2023-2034)
- 7.5.4.3. South America Aptamers Market Size in USD million (2023-2034)
- 8. Aptamers Market Competitive Landscape
- 8.1. Competitive Analysis
- 8.2. Company Share Analysis (Premium Offering)
- 9. Aptamers Market Startup Funding and Investment Trends
- 10. Aptamers Market Company and Product Profiles
- 10.1. Illumina, Inc. (SomaLogic)
- 10.1.1. Company Overview
- 10.1.2. Company Snapshot
- 10.1.3. Financial Overview
- 10.1.4. Product/Pipeline Portfolio
- 10.1.5. Strategic Initiatives / Entropy
- 10.2. Aptamer Group plc
- 10.2.1. Company Overview
- 10.2.2. Company Snapshot
- 10.2.3. Financial Overview
- 10.2.4. Product/Pipeline Portfolio
- 10.2.5. Strategic Initiatives / Entropy
- 10.3. Base Pair Biotechnologies, Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Snapshot
- 10.3.3. Financial Overview
- 10.3.4. Product/Pipeline Portfolio
- 10.3.5. Strategic Initiatives / Entropy
- 10.4. NeoVentures Biotechnology Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Snapshot
- 10.4.3. Financial Overview
- 10.4.4. Product/Pipeline Portfolio
- 10.4.5. Strategic Initiatives / Entropy
- 10.5. TriLink BioTechnologies, LLC (Maravai LifeSciences)
- 10.5.1. Company Overview
- 10.5.2. Company Snapshot
- 10.5.3. Financial Overview
- 10.5.4. Product/Pipeline Portfolio
- 10.5.5. Strategic Initiatives / Entropy
- 10.6. TME Pharma AG
- 10.6.1. Company Overview
- 10.6.2. Company Snapshot
- 10.6.3. Financial Overview
- 10.6.4. Product/Pipeline Portfolio
- 10.6.5. Strategic Initiatives / Entropy
- 10.7. Astellas Pharma Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Snapshot
- 10.7.3. Financial Overview
- 10.7.4. Product/Pipeline Portfolio
- 10.7.5. Strategic Initiatives / Entropy
- 10.8. Aptagen LLC
- 10.8.1. Company Overview
- 10.8.2. Company Snapshot
- 10.8.3. Financial Overview
- 10.8.4. Product/Pipeline Portfolio
- 10.8.5. Strategic Initiatives / Entropy
- 10.9. Vivonics Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Snapshot
- 10.9.3. Financial Overview
- 10.9.4. Product/Pipeline Portfolio
- 10.9.5. Strategic Initiatives / Entropy
- 10.10. NEC Corporation
- 10.10.1. Company Overview
- 10.10.2. Company Snapshot
- 10.10.3. Financial Overview
- 10.10.4. Product/Pipeline Portfolio
- 10.10.5. Strategic Initiatives / Entropy
- For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
- 11. KOL Views
- 12. Project Approach
- 13. About DelveInsight
- 14. Disclaimer and Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
